Compare AZTA & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZTA | PAHC |
|---|---|---|
| Founded | 1978 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 1996 | 2014 |
| Metric | AZTA | PAHC |
|---|---|---|
| Price | $31.47 | $37.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 4 |
| Target Price | $40.60 | ★ $41.25 |
| AVG Volume (30 Days) | ★ 705.2K | 197.5K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.91% |
| EPS Growth | N/A | ★ 104.20 |
| EPS | N/A | ★ 2.43 |
| Revenue | $593,821,000.00 | ★ $833,350,000.00 |
| Revenue This Year | $6.99 | $17.03 |
| Revenue Next Year | $5.98 | $3.82 |
| P/E Ratio | ★ N/A | $15.74 |
| Revenue Growth | N/A | ★ 4.12 |
| 52 Week Low | $15.93 | $28.25 |
| 52 Week High | $41.73 | $60.08 |
| Indicator | AZTA | PAHC |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 57.62 |
| Support Level | $27.00 | $36.31 |
| Resistance Level | $37.86 | $37.92 |
| Average True Range (ATR) | 1.47 | 1.64 |
| MACD | -0.60 | 0.19 |
| Stochastic Oscillator | 12.86 | 50.17 |
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.